"The companies' shared expertise, combined with AbbVie's broad late-stage oncology pipeline, has the potential to transform the cancer treatment landscape for hematological malignancies and improve patient outcomes and quality of life," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.
The newly formed Tanner Pharma Group will continue to focus on patients by providing...
Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office...
Sigma-Aldrich Corporation has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate (ADC) manufacturing.
Pfizer recently announced their acquisition of a minority equity interest in AM-Pharma, and secured an exclusive option to acquire the remaining equity in the company.
Sigma-Aldrich Corporation's new facility will support commercial-scale gene therapy production, testing and filling.
Juno Therapeutics, a biopharmaceutical company focused on cancer treatment, announced today that it has acquired Stage Cell Therapeutics GmbH.
Inovio Pharmaceuticals announced that the company has initiated a phase I trial to evaluate the safety, tolerability and immune responses of their DNA immunotherapy for Ebola.
Mexico's public health system has suspended infant vaccines and mounted an investigation after vaccinations for tuberculosis, rotovirus and Hepatitis B resulted in devestation for an impoverished southern community.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer provided an update of its three clinical development programs.
Bellicum Pharmaceuticals, Inc. today announced that it has entered into a lease agreement to enable in-house cell therapy manufacturing to supply clinical trials.
MorphoSys AG announced today that it has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.
Alexion Pharmaceuticals will pay a huge premium to buy fellow rare disease treatment maker Synageva BioPharma in an $8.4-billion deal for a company with no products on the market.
PlasmaTech Biopharmaceuticals has acquired Abeona Therapeutics, a company engaged in the development and commercialization of therapies for patients with lysosomal storage diseases.
Amyris, Inc., the industrial bioscience company, today announced financial results for the first quarter of 2015.
While it’s a vital link between a facility and the pharmaceuticals shipped in and out every day, the loading dock presents the greatest opportunity for energy losses and damage to precious materials and products.
Shared service management is an important development in the collaboration between an organization’s supporting services, and can make an organization more Lean.
Downstream processing continues to impact capacity at the majority of biopharmaceutical manufacturing facilities.
Ciclofilin Pharmaceuticals Inc., a hepatitis B virus ("HBV") drug developer, announced today the appointment of Michael Kamdar as President.
The GMP commercial launch manufacturing facility in Cranbury will focus on antibody biosimilars.
Capsugel has manufactured Phase 2 clinical trial supplies for a dry powder inhalation (DPI) formulation that efficiently delivers biotherapeutics to the lung.
Immune Pharmaceuticals and STC Biologics are entering into a strategic partnership to accelerate the development of NanomAbs, a new generation of Antibody Nanoparticle Conjugates allowing the targeted delivery of chemo-therapeutics.
Sigma-Aldrich Corporation today announced that SAFC Commercial, its custom manufacturing services business unit, has introduced ADC Express preclinical development services.
TESARO, Inc., an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2015 and provided an update on the Company's development programs.
The spend on R&D for mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex.
Enteris BioPharma seeks to stand out from a pack of contract manufacturers with experience, flexibility, and quality. While much of market is focused on mammalian cell cultures, Enteris has “carved out their own niche” in microbial expression systems.
The company says it is tripling production of its new, fast-acting, inhalable insulin for diabetes at its Danbury plant.
Merck easily beat Wall Street expectations despite first-quarter profit plunging 44 percent. The company was hurt by the sale of its consumer health business, unfavorable currency exchange rates and competition to some drugs.
- Page 1